Abstract: Low-dose IL-2 could be an effective therapeutic choice for treating bullous pemphigoid (BP) caused by PD-1/PD-L1 inhibitors. This case report highlights the successful management of drug-induced BP using low-dose IL-2 to restore immune balance through regulatory T cell (Treg) activation.
Introduction
Immune checkpoint inhibitors (ICIs), such as PD-1 and PD-L1 inhibitors, have revolutionized oncology by enhancing the body's anti-tumor immune response. However, these therapies frequently trigger immune-related adverse events (irAEs). Bullous pemphigoid (BP) is a rare but debilitating irAE characterized by the immune system attacking the dermal-epidermal junction, leading to painful blistering. Standard management typically relies on long-term systemic corticosteroids or immunosuppressants, which carry significant side effects and may potentially interfere with the anti-cancer efficacy of the immunotherapy. There is a critical need for targeted therapies that manage irAEs without compromising cancer treatment.
Case Presentation and Methods
Researchers presented the case of a 31-year-old female with hepatocellular carcinoma who developed BP after 15 months of treatment with the PD-1 inhibitor karelizumab. Notably, the patient's blisters were predominantly located around hair follicles, suggesting a specific perifollicular targeting possibly due to "epitope spreading" induced by the PD-1 inhibitor.
To treat the BP while maintaining her oncology care, clinicians employed a standardized regimen of low-dose interleukin-2 (IL-2):
- Dosage: 0.8 million units (MU) administered subcutaneously every other day.
- Schedule: Seven doses per course, for a total of three courses separated by two-week intervals.
- Combination Therapy: Low-dose IL-2 was used alongside topical halometasone and oral doxycycline.
Efficacy was monitored using the Bullous Pemphigoid Disease Area Index (BPDAI), the 5D-Itch Scale (5D-IS), and the Dermatology Life Quality Index (DLQI). Longitudinal laboratory analyses of lymphocyte subsets and cytokine levels (IL-4, IL-8, and IL-10) were also performed.
Key Insights: The IL-2 Paradox
IL-2 acts as a "double-edged sword" depending on the dosage. While high doses stimulate effector T-cells to promote inflammation (often used in cancer therapy), low doses selectively activate and expand Regulatory T cells (Tregs). These Tregs are essential for suppressing overactive immune responses and maintaining self-tolerance. Previous studies have indicated that BP patients often exhibit reduced Treg counts; this report suggests that low-dose IL-2 can "reset" this immune balance in the context of drug-induced autoimmunity.
Results
The treatment yielded significant clinical and biological improvements:
- Rapid Recovery: Substantial healing of skin lesions was observed within just two weeks.
- Clinical Scores: The BPDAI score plummeted from 39 to 9. The itch scale (5D-IS) dropped from 33 to 16, and the quality of life index (DLQI) improved from 15 to 2.
- Biological Markers: Post-treatment analysis showed a significant downregulation of B-cells, CD4+ T-cells, and CD8+ T-cells.
- Cytokine Normalization: Pro-inflammatory cytokines IL-4 and IL-8, which were elevated at baseline, returned to normal levels following the IL-2 regimen.
Conclusion
This case demonstrates that low-dose IL-2 can effectively manage ICI-induced bullous pemphigoid, allowing the patient to continue vital cancer treatment. While these results are compelling, the study is limited by its single-patient sample size. Future controlled clinical trials are necessary to confirm the reproducibility of this response and to ensure that low-dose IL-2 does not diminish the long-term anti-tumor effects of checkpoint inhibitors.
Summary updated